Table 1 General characteristics of the T2DM and controls
T2DM (n = 237) | Control (n = 93) | P value | |
|---|---|---|---|
age(years) | 64.41 ± 9.23 | 64.61 ± 7.62 | 0.900 |
Menopause’s years(years) | 13.77 ± 9.55 | 14.13 ± 13.21 | 0.783 |
Diabetic duration(years) | 12.08 ± 8.64 | None | NA |
Fasting glucose(mmol/L) | NA | 5.32 ± 0.60 | NA |
HbA1c | 9.36 ± 2.35 | 5.67 ± 0.33 | < 0.001 |
PINP(ng/ml) | 48.47 ± 27.27 | 65.86 ± 21.06 | < 0.001 |
PTH(pg/ml) | 43.43 ± 30.05 | 50.34 ± 20.85 | < 0.001 |
N-MID osteocalcin(ng/ml) | 17.42 ± 9.50 | 23.67 ± 7.58 | < 0.001 |
β-CTX(ng/ml) | 0.57 ± 0.28 | 0.55 ± 0.21 | 0.868 |
25(OH)D3(ng/ml) | 11.22 ± 6.83 | 18.39 ± 5.62 | < 0.001 |
TC(mmol/L) | 4.54 (3.79–5.31) | 5.25(4.60,6.02) | < 0.001 |
TG(mmol/L) | 1.45 (1.03–2.17) | 1.21(0.95,1.67) | 0.002 |
HDL-c(mmol/L) | 1.16 (0.96–1.41) | 1.58(1.34,1.82) | < 0.001 |
LDL-c(mmol/L) | 2.67 (1.99–3.30) | 3.23(2.46,3.85) | < 0.001 |
History of fracture, n (%) | 17 (7.17%) | None | NA |
Microvascular complications, n (%) | 183 (77.22%) | None | NA |
Macrovascular complications, n (%) | 144 (60.76%) | None | NA |
Treatment | None | NA | |
Insulin, n(%) | 63 (26.58%) | None | NA |
Oral anti-diabetic agents, n (%) | 23 (9.70%) | None | NA |
Insulin+Oral anti-diabetic agents, n (%) | 151 (63.71%) | None | NA |
Use of statin medication | 112 (47.26%) | None | NA |